{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:57:15Z","timestamp":1788976635060,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp; Dem Diag Ass &amp; Dis Mo"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lecanemab, an anti\u2010amyloid\u2010beta antibody, is approved in over 40 countries. Patient demographic data exist for the US but are limited elsewhere. This study examined early real\u2010world lecanemab use in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using claims data from 18 municipalities, we identified patients prescribed lecanemab between December 2023 and September 2024. The study outcome was the discontinuation rate, with discontinuation defined as a \u226542\u2010day prescription gap. Covariates included age, sex, long\u2010term care certification, municipality size, comorbidities, Mini\u2010Mental State Examination (MMSE) score, and Clinical Dementia Rating (CDR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 123 lecanemab recipients (median age: 76 years, interquartile range: 73\u201379 years; women: 73.2%). Most had mild impairment: 60.9% with MMSE \u226524 and 79.3% with CDR 0.5. The discontinuation rate was 1.04\/100 person\u2010months, with most occurring within 1.5 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this first Asian report, lecanemab was mainly prescribed to older women with milder cognitive impairment. Early discontinuation may reflect cautious adoption in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/dad2.70273","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T03:04:53Z","timestamp":1771815893000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Initial real\u2010world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement &amp; Fair Evidence (LIFE) Study"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9096-6957","authenticated-orcid":false,"given":"Kengo","family":"Kawaguchi","sequence":"first","affiliation":[{"name":"Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"},{"name":"Department of Orthopaedic Surgery Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-1548","authenticated-orcid":false,"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_3_1","unstructured":"Eisai Co. Ltd.Austria and Germany to Become the First Markets in the European Union (EU) to Launch LEQEMBI\u00ae (Lecanemab).2025: Eisai Co. Ltd."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.11711"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00756-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26819"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20210513"},{"key":"e_1_2_8_8_1","unstructured":"LIFE Study: Longevity Improvement & Fair Evidence Study.(Accessed 3 December 2025) Available from:https:\/\/life.lifestudylab.org\/"},{"key":"e_1_2_8_9_1","unstructured":"Ministry of Health L.a.W. Japan.Guidelines for the Proper Use Promotion of Lecanemab (genetically recombined).2023 Ministry of Health Labour and Welfare."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003661"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2019.0246"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2020-216158"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-17-0177"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.159"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dad2.70273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:12:21Z","timestamp":1781089941000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/dad2.70273"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70273","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70273"}}